Clinical Dilemmas in Diabetes

70 70. Brunner EJ et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 2006; 29(1):26–31.

71 71. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta‐analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215–2222.

72 72. Rao Kondapally Seshasai S et al. Diabetes mellitus, fasting glucose, and risk of cause‐specific death. N Engl J Med. 2011; 364(9):829–841.

73 73. Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25(12):2165–2171.

74 74. Hamman RF et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006; 29(9):2102–2107.

75 75. Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11):866–875.

76 76. Ratner R et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005; 28(4):888–894.

77 77. Florez H et al. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012; 27(12):1594–1601.

78 78. Diabetes Prevention Program Research Group. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care. 2012; 35(4):723–730.

79 79. Pan XR et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20(4):537–544.

80 80. Gong Q et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30‐year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7(6):452–461.

81 81. Madsen KS et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019; 12:CD008558.

82 82. le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet. 2017; 389(10077):1399–1409.

83 83. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4):319–328.

84 84. DeFronzo RA et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364(12):1104–1115.

85 85. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541):1096–1105.

86 86. Knowler WC et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005; 54(4):1150–1156.

87 87. Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1):155–161.

88 88. Chiasson JL et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP‐NIDDM randomised trial. Lancet. 2002; 359(9323):2072–2077.

89 89. Group NS et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16):1477–1490.

90 90. Eriksson JG et al. Long‐term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance. J Intern Med. 2006; 259(6):553–560.

91 91. Kanaya AM et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med. 2003; 138(1):1–9.

92 92. Margolis KL et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004; 47(7):1175–1187.

93 93. Sawicki PT and Kaiser T. Response to Chiasson et al.: Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP‐NIDDM Trial data. Diabetologia. 2004; 47(6):976–977.

94 94. Lindblad U et al. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). Diabetes Obes Metab. 2011; 13(2):185–188.

95 95. Pittas AG et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019; 381(6):520–530.

96 96. NAVIGATOR Study Group et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16):1463–1476.

97 97. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355(15):1551–1562.

98 98. Carlsson LM et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367(8):695–704.

99 99. Pories WJ et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992; 215(6):633–642; discussion 643.

100 100. Smith AD et al. Physical activity and incident type 2 diabetes mellitus: a systematic review and dose‐response meta‐analysis of prospective cohort studies. Diabetologia. 2016; 59(12):2527–2545.

101 101. Grontved A et al. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med. 2012; 172(17):1306–1312.

102 102. Salas‐Salvado J et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med. 2014; 160(1):1–10.

103 103. American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes – 2020. Diabetes Care. 2020; 43(Suppl 1):S32–S36.

104 104. Hu W et al. Association of elevated glycosylated hemoglobin A1c with hyperfiltration in a middle‐aged and elderly Chinese population with prediabetes or newly diagnosed diabetes: a cross‐sectional study. BMC Endocr Disord. 2015; 15:47.

105 105. Kannan MA et al. Prevalence of neuropathy in patients with impaired glucose tolerance using various electrophysiological tests. Neurol India. 2014; 62(6):656–661.

106 106. Wu JS et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007; 92(10):3885–3889.

107 107. Holman RR et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2017; 5(11):877–886.

Paolo Pozzilli and Silvia Pieralice

Department of Endocrinology & Diabetes, Campus Bio‐Medico University of Rome, Rome, Italy

Making an early diagnosis of type 1 diabetes can permit intervention with agents that could modify the course of disease.